Outcome, Fatal
Conditions
Keywords
Sugammadex, Colorectal surgery, postoperative complication
Brief summary
This study is retrospective study. The purpose of this study is checking the effect of sugammadex on the outcome after colorectal surgery. The outcome is compared among the 2 groups, sugammadex group and non-sugammadex group. The primary parameters of outcome are length of stay, readmission rate, postoperative complications, time interval for first successful oral intake.
Detailed description
Abdominal surgery, like colorectal surgery, needs more than moderate neuromuscular block during surgery. After the surgery, reversal agent of neuromuscular blocking agent is given almost every pateints who underwent general anesthesia. Classic reversal agent is cholinesterase inhibitor, like pyridostigmine and neostigmine. Its action mechanism is competetive antagonist of rocuronium. But cholinesterase inhibitor cannot make complete reversal in moderate or deep neuromuscular block. Its incomplete reversal which is called residual block cause respiratory complications and prolongation hospital stay. Sugammadex has different mechanism compared to cholinesterase inhibitor. It captures neuromuscular agent, especially rocuronium, and prevent rocuronium's action. Even in deep neuromuscular block, sugammadex can reverse the action of rocuronium, and its reversal effect is fater and more reliable compared to cholinesterase inhibitor. Previous studies focused on only short term outcome of sugammadex, like postanesthetic care unit (PACU) discharge time, respiratory complications in PACU. But in this study, longer term outcome will be comapred between sugammadex group and cholinesterase inhibitor group (pyridostigmine).
Interventions
DRUGSugammadex
Sugammadex injection as a reverse agent of neuromuscular blocking
Sponsors
Ajou University School of Medicine
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
21 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Subjects aged 21\ 80 * Subjects who took colorectal surgery due to colon or rectal cancer from Jan, 2012 to Dec, 2017
Exclusion criteria
* Emergency surgery * Paraplegia or quadriplegia * Bedridden state d/t various reason * Neuromuscular disease * Combined operation wth other surgery
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Length of stay | admission to discharge (within 1 month) | Length of stay in hospital |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Readmission rate | 30 days after discharge | Readmission or ER visit within 30 days after discharge |
| postoperative complication rate | after colorectal surgery, within 30 days | postoperative complications, heart, lung, kidney, neurovascular, infection etc Check by review discharge summary note, consultation note, and postoperative laboratory tests |
| Time to first successful oral intake | within 30 days | time interval between end of surgery and the first successful oral intake |
Countries
South Korea
Outcome results
None listed